CoVFlu-II One Step Real-Time PCR Kit

Product Overview

Respiratory infections caused by COVID-19 and influenza viruses often present with overlapping clinical symptoms, making rapid and accurate differential diagnosis essential for effective patient management and infection control. Symptoms such as fever, cough, sore throat, fatigue, nasal congestion, myalgia, and respiratory distress may occur in both COVID-19 and influenza infections, particularly during seasonal outbreaks and co-circulation periods. Reliable molecular testing capable of simultaneously identifying multiple respiratory pathogens is therefore critical for timely clinical decision-making and epidemiological surveillance.

The CoVFlu-II One-Step RT-PCR Kit from Genes2Me is a multiplex molecular assay designed for the qualitative detection of SARS-CoV-2, Influenza A, and Influenza B from respiratory specimens in a single RT-PCR reaction. The assay also enables rapid differentiation between COVID-19 and influenza infections, helping laboratories streamline respiratory pathogen testing while reducing turnaround time and reagent consumption.

Targets:
SARS-CoV-2 (COVID-19), Influenza A (Flu-A), and Influenza B (Flu-B)
Technology:
Multiplex One-Step Real-Time RT-PCR
Detection:
Qualitative (Detected / Not Detected)
Sample Type:
Nasopharyngeal and oropharyngeal swabs in Viral Transport Media (VTM)
Certification:
CE-IVD
CoVFlu-II-One-Step

How the Assay Works

The CoVFlu-II One-Step RT-PCR Kit utilizes multiplex real-time reverse transcription PCR technology to simultaneously detect three major respiratory viral targets in a single reaction:

  • SARS-CoV-2 (COVID-19)
  • Influenza A
  • Influenza B

Specific primers and fluorescent probes amplify and detect viral RNA in real time through fluorescence monitoring across multiple detection channels. The assay includes an integrated Internal Control to monitor PCR inhibition. This helps minimize the risk of false-negative results caused by sample-related inhibitors or technical issues during processing.

Why Multiplex Testing Matters

COVID-19 and influenza infections share many overlapping clinical symptoms, making it difficult to differentiate between them based on symptoms alone. Multiplex testing enables simultaneous detection of SARS-CoV-2, Influenza A, and Influenza B within a single assay, allowing clinicians to rapidly distinguish between these respiratory infections and make timely treatment and isolation decisions.

By combining multiple respiratory pathogen targets into one reaction, shortens reporting time compared with performing separate individual tests. The multiplex design also enhances diagnostic confidence during seasonal respiratory outbreaks when co-infections or circulating viral variants may complicate clinical diagnosis.

Sample Type & Reporting Output

Sample Type:
Nasopharyngeal and oropharyngeal swabs collected in Viral Transport Media (VTM)
Reporting Output:
Qualitative detection of:
SARS-CoV-2 (COVID-19)
Influenza A (Flu-A)
Influenza B (Flu-B)
Targets Detected:
COVID-19, Influenza A, and Influenza B viral RNA

Key Features & Benefits

Simultaneous detection of COVID-19 and influenza viruses

Enables rapid differentiation between SARS-CoV-2, Influenza A, and Influenza B infections within a single multiplex RT-PCR assay.

One-step multiplex workflow

Combines reverse transcription and real-time PCR amplification into a streamlined single-step process, reducing hands-on time and improving workflow efficiency.

Internal control in every reaction

Integrated Cy5-labelled internal control monitors PCR inhibition and validates assay integrity for every sample, ensuring dependable reporting accuracy.

Compatible with leading real-time PCR platforms

Validated on multiple widely used PCR systems including QuantStudio 5 Real-Time PCR System, CFX96 Real-Time PCR System, LightCycler 480 System, RapiCycler 96 Real Time PCR System.

Complete reagent system included

Supplied with primer and probe mix, qRT-PCR master mix, positive control template, and RNase/DNase-free water for simplified assay preparation and standardized workflow performance.

Reliable low viral load detection

Ct cut-off value of ≤35 enables dependable qualitative detection of respiratory viral RNA, including samples with lower viral concentrations.

Applications

  • Clinical & Hospital Laboratories: Supports rapid differentiation of COVID-19 and influenza infections for effective patient management and infection control measures.
  • Respiratory Infection Screening Programs: Enables simultaneous detection of multiple respiratory pathogens during seasonal outbreaks and respiratory surveillance programs.
  • Public Health & Epidemiological Surveillance: Assists healthcare systems in monitoring co-circulation trends of SARS-CoV-2 and influenza viruses.
  • Reference & Molecular Diagnostic Laboratories: High-throughput multiplex workflow supports efficient respiratory pathogen testing across diverse laboratory settings.

Analytical Performance

  • Multiplex qualitative detection of SARS-CoV-2, Influenza A, and Influenza B in a single assay
  • Ct cut-off value of ≤35 for positive detection
  • High analytical sensitivity and specificity for respiratory pathogen detection
  • Compatible with standard viral RNA extraction workflows and multiple real-time PCR platforms
  • Designed to reduce false-negative results and improve workflow efficiency during respiratory outbreak testing
  • Complete reagent system included for standardized and reliable assay performance

Data Analysis and Report

ViralDtect-II

CoVFlu-II One Step RT PCR specific amplification plot of Treponema pallidum Positive Control (HEX Channel) along with Internal Control (Cy5 Channel)

Ordering Information

Commercial Name Old Cat No. New Cat No. Pack Size
CoVFlu-II One Step Real-Time PCR Kit G2M709821 G2M709821-1 50 Tests

Product Enquiry Form

Other Products

Rapi-Q Series
Rapi-Q

Rapid and Compact Point-of-care RT-PCR Testing Solution.

Rapi-X96
RAPiCycler-96

Real time PCR system to process 96 samples.
TRapi-X96
Rapi-X16

Compact Nucleic Acid Extraction System Ideal for Point-of-Care Testing

Since its inception in 2016, Genes2me has been constantly striving towards setting a benchmark in the diagnostics space by introducing premium quality (Made in India) diagnostic kits which are CE-IVD, ISO-13485:2016, and ISO 9001:2015 certified, assuring our clients of unparalleled quality and compliance with international standards.

© 2025 Genes2me. All rights reserved.